Nasdaq GlobeNewswire

Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

SAN DIEGO, March 23, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016.

Axsome Therapeutics to Present at the 16th Annual Needham Healthcare Conference

NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, M.D., Axsome’s Chief Executive Officer, will present a corporate overview at the 16th Annual Needham Healthcare Conference on April 5, 2017 at 8:40 AM Eastern Time. The conference will be held at The Westin NY Grand Central Hotel in New York, NY.

Vital Therapies Announces Pricing of Public Offering of Common Stock

 

SAN DIEGO, March 22, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing ELAD®, a cell-based therapy targeting the treatment of acute forms of liver failure, today announced the pricing of an underwritten public offering of 8,750,000 newly issued shares of its common stock at a price to the public of $4.00 per share for gross proceeds of approximately $35.0 million.  All of the shares are being sold by Vital Therapies. The offering is expected to close on or about March 27, 2017, subject to customary closing conditions. In addition, Vital Therapies has also granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

BeyondSpring Chief Medical Officer to Present on Lead Asset Plinabulin for Chemotherapy-Induced Neutropenia Prevention at BIO-Europe Spring 2017

 

NEW YORK, March 22, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company’s Chief Medical Officer and Head of Business Development, Ramon Mohanlal, M.D., Ph.D., M.B.A., will present clinically and statistically significant data on BeyondSpring’s lead asset, Plinabulin, for the prevention of chemotherapy-induced Neutropenia at this year’s BIO-Europe Spring meeting in Barcelona, Spain.  

Cytokinetics Announces Preclinical Data for CK-2127107 Presented at MDA Scientific Conference

 

SOUTH SAN FRANCISCO, Calif., March 22, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that preclinical data for CK-2127107 were presented at the MDA Scientific Conference in Arlington, VA, showing that this next-generation fast skeletal troponin activator (FSTA) improves muscle function in mouse models of spinal muscular atrophy (SMA). In collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas"), Cytokinetics is developing CK-2127107 as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares

 

PHILADELPHIA and OXFORD, United Kingdom, March 21, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All of the ADSs in the offering are to be sold by Adaptimmune, with net proceeds to be used to advance Adaptimmune’s wholly-owned pipeline of SPEAR® T-cell candidates through clinical trials as well as for other general corporate purposes.

USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative Pathway Factor D Inhibitors

 

NEW HAVEN, Conn., March 21, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued the first U.S. Patent to Achillion resulting from its complement factor D research program. U.S. Patent No. 9,598,446 has been granted with claims to compositions of matter for compounds that inhibit complement factor D activity, a key mediator in the complement alternative pathway (AP). In addition, the USPTO has issued Notices of Allowance of four additional U.S. patent applications owned by Achillion, also with claims to compositions of matter, that are expected to issue as patents over the next few months.

Vital Therapies Announces Proposed Public Offering of Common Stock

 

SAN DIEGO, March 21, 2017 (GLOBE NEWSWIRE) -- Vital Therapies, Inc. (Nasdaq:VTL), a biotherapeutic company developing the ELAD® System, a cell-based therapy targeting the treatment of liver failure, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering. In addition, Vital Therapies expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the public offering at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Vital Therapies currently plans to use the net proceeds from this offering for the continuing clinical development of the ELAD System, working capital and other general corporate purposes.

Axsome Therapeutics Announces Pricing of Its Public Offering of Common Stock

 

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the pricing of its underwritten public offering of 3,743,316 shares of its common stock at a public offering price of $3.74 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Axsome, are expected to be approximately $14 million. In addition, Axsome granted the underwriter a 30-day option to purchase up to 561,497 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All shares in the offering will be sold by Axsome.

CURE Pharmaceutical Announces Product Development and Licensing Deal with Diverse International Pharmaceutical Company Meroven, Ltd.

OXNARD, Calif., March 21, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, cannabinoid molecules and new chemical entities (NCEs), today announces a product development and license agreement with Dublin, Ireland-based Meroven, Ltd. (“Meroven”), for the development of oral thin film delivery for several molecules.

Arbutus Announces Year-End 2016 Financial Results

3 HBV Product Candidates in the Clinic in 1Q17
Cash Runway into Late 2018
Company to Host a Corporate Update Conference Call Today at 2:00 PM ET

Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2016 Financial Results

 

BERKELEY HEIGHTS, N.J., March 21, 2017 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce fourth quarter and full year 2016 financial results on Tuesday, March 28, 2017. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day. 

Pain Therapeutics Announces Positive Regulatory Guidance for REMOXY™ ER

AUSTIN, Texas, March 20, 2017 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE) today announced positive regulatory guidance from a recent meeting with the U.S. Food and Drug Administration (FDA) regarding REMOXY (extended-release oxycodone capsules CII), its lead drug candidate.  The Company will host a conference call tomorrow morning at 8am EDT to discuss REMOXY, and to present a corporate update around partnership discussions and advances to its pipeline.

Axsome Therapeutics Announces Proposed Public Offering of Common Stock

 

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Axsome intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BeyondSpring Lead Asset Plinabulin's Anti-Cancer Mechanism Accepted for Poster Presentation at the 2017 Keystone Symposia in British Columbia

 

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies, today announced that an abstract on the molecular action describing the immunological involvement in the anti-cancer effect of BeyondSpring’s lead asset, Plinabulin, has been accepted for poster presentation at this year’s Keystone Symposia’s “Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology” meeting in Whistler, British Columbia, Canada.

Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.  

Cytokinetics Announces Additional Results From COSMIC-HF Presented at ACC.17

 

SOUTH SAN FRANCISCO, Calif., March 20, 2017 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq:CYTK) today announced that additional results from COSMIC-HF (Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluating omecamtiv mecarbil in patients with chronic heart failure, were presented by Tor Biering-Sørensen, MD, PhD, Postdoctoral Research Fellow, Division of Cardiology, Brigham & Women’s Hospital and Harvard Medical School, in a Poster Session at the American College of Cardiology’s 66th Annual Scientific Session (ACC.17) in Washington, D.C. The results presented showed that omecamtiv mecarbil improved myocardial deformation, a marker of myocardial function that has been related to outcomes. Omecamtiv mecarbil, a novel investigational cardiac myosin activator that increases cardiac contractility, is being developed by Amgen in collaboration with Cytokinetics for the potential treatment of heart failure.

Amydis Diagnostics Awarded NIH Grant to Further Investigate Innovative Technology for Early Detection of Alzheimer’s Disease

 

SAN DIEGO, March 20, 2017 (GLOBE NEWSWIRE) -- Amydis Diagnostics, Inc., a preclinical stage, privately-held pharmaceutical company developing proprietary chemistry and innovative approaches to detection of amyloid-related neurodegenerative disorders such as Alzheimer’s disease, announced that they received a Phase 2 SBIR grant award by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). The grant award for $1.8 million will fund research and development of a novel ophthalmic diagnostic probe for Alzheimer’s Disease. The company previously was awarded a Phase 1 grant from 2015-2016. 

Akari Therapeutics Announces R&D Day on April 24, 2017

NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will be hosted by members of Akari’s executive leadership team and will feature presentations from investigators and independent scientific advisors. The meeting will cover three main areas:

Kraig Biocraft Laboratories’ Management Completes Site Survey with Vietnamese Officials

ANN ARBOR, Mich., March 17, 2017 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of spider silk based fibers, announced today that the Company’s management just completed a site survey trip in Quang Nam province, Vietnam, with Vietnamese officials.